West Pharmaceutical Services, Inc.(WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest News & Analysis
West Pharmaceutical Services (WST) Faces Scrutiny: What Investors Need to Know
West Pharmaceutical Services (WST) faces scrutiny over revised 2025 guidance and a securities law investigation, impacting investor confidence and stock performance.
West Pharmaceutical Services (WST): Securities Fraud Investigation Impact
West Pharmaceutical Services (WST) faces a securities fraud investigation after lowered 2025 guidance, impacting stock and investor confidence.
West Pharmaceutical Services (WST): Investigation and Market Impact
West Pharmaceutical Services (WST) faces a securities fraud investigation amid lowered 2025 guidance. Despite challenges, long-term growth potential exists.
West Pharma (WST): Securities Fraud Investigation & GLP-1 Growth
West Pharmaceutical Services (WST) faces a securities fraud investigation and lowered guidance, but opportunities in GLP-1 medications offer potential growth.
West Pharmaceutical Services (WST): Securities Investigation, GLP-1 Growth
West Pharmaceutical Services (WST) faces a securities investigation amid lowered 2025 guidance, impacting investor sentiment. GLP-1 medication demand offers growth, but supply chain issues persist.
West Pharmaceutical Services (WST): Investigation and Market Impact
West Pharmaceutical Services (WST) navigates a securities law investigation and lowered guidance amidst GLP-1 market growth. Investors should monitor key developments.
West Pharma (WST): Securities Investigation and Guidance Impact
Analysis of West Pharmaceutical Services (WST) amidst lowered guidance, a securities investigation, and declining profit margins. Key insights for investors.
West Pharmaceutical Services, Inc. News and Analysis
Analysis of West Pharmaceutical Services, Inc. (WST) amid securities fraud investigations and revised guidance. Dive into market reactions and future outlook.
West Pharmaceutical Services: Navigating Uncertainty Amidst Investigation
West Pharmaceutical Services navigates uncertainty amid lowered guidance and a securities probe. Key is understanding Q4 results, industry trends, and analyst ratings.
West Pharmaceutical Services (WST) Under Pressure: Guidance Revision
West Pharmaceutical Services faces scrutiny after revising its 2025 guidance downwards, triggering securities fraud investigations. Investors should remain cautious.
West Pharma's Dividend Under Pressure: Navigating Headwinds
West Pharmaceutical Services faces dividend pressure amidst market turbulence, securities fraud allegations, and lowered guidance. A detailed analysis of WST's challenges and prospects.
West Pharmaceutical Services: Stock Plunge Amid Weak 2025 Guidance
In-depth analysis of West Pharma's Q4 earnings and 2025 guidance, driven by currency headwinds, destocking trends, and strategic capacity expansion.
West Pharmaceutical Services Navigates 2025 Challenges
Detailed analysis reveals robust Q4 earnings but 2025 guidance challenges from strong currency headwinds and client inventory reductions.